摘要
目的:在我们前期体外细胞和裸鼠成瘤实验研究结果的基础上,检测新癌基因REDD1和Bcl-2在人卵巢高级别浆液性癌组织中的表达,分析其与临床病理因子之间的关系及二者的相关性。方法:应用免疫组织化学链霉素抗生物素-过氧化物酶复合法(S-P)检测REDD1、Bcl-2在50例卵巢高级别浆液性癌组织中的表达。结果:REDD1在Ⅲ、Ⅳ期高级别浆液性癌组织中的表达明显高于Ⅰ~Ⅱ期(P<0.05),在有腹水病例组中的表达高于无腹水组(P<0.05);Bcl-2在Ⅲ、Ⅳ期高级别浆液性癌组织中的表达明显低于Ⅰ~Ⅱ期(P<0.05),在无腹水的病例组中的表达高于有腹水组(P<0.05);REDD1和Bcl-2在卵巢癌组织中的表达与化疗反应无关(P>0.05)。结论:REDD1、Bcl-2可能参与了卵巢高级别浆液性癌的发生,联合检测二者的表达可能有助于卵巢癌临床预后的评估。
Objective: Based on our previous in vitro and in vivo experiments,investigate the correlation between the expression of new oncogene REDD1,Bcl-2 and clinical-pathologic factors in human ovarian high-grade serous carcinoma.Methods:Immunohistochemical staining of REDD1 and Bcl-2 expression were analyzed in 50 primary ovarian high-grade serous carcinoma using tissue microarray.The correlation between the expression of the REDD1,BCL-2 and clinical factors(stage,ascites and chemotherapy response) were analyzed.Results:The expression of REDD1 was significantly higher in the FIGO stage III、IV than stageⅠ/Ⅱ tissues(P 0.05),and significantly higher in the patients with ascites group than without it(P0.05) in ovarian high-grade serous carcinoma tissues.Furthermore,the expression of Bcl-2 was significantly lower in the FIGO stage III,IV than stageⅠ/Ⅱ(P0.05),and significantly lower in the patients with ascites group than without it in ovarian high-grade serous carcinoma tissues(P0.05).There was no correlation between the expression of REDD1,Bcl-2 and the patients' response to chemotherapy in ovarian high-grade serous carcinoma(P 0.05).Conclusion:Conclusion: REDD1and Bcl-2 may involve in the initiation and progression of human ovarian high-grade serous carcinoma.Detection of expression of REDD1 and Bcl-2 may have prognostic value in ovarian high-grade serous carcinoma.
出处
《农垦医学》
2012年第3期193-198,共6页
Journal of Nongken Medicine
基金
国家自然科学基金(81160316)
国家人力资源和社会保障部-留学回国人员科技活动项目-新疆生产建设兵团重点领域科技攻关项目(2011BA038)
石河子大学医学院基础与临床医学联合基金资助项目(LHJJ2010B01)